Modality
Bispecific Ab
MOA
CGRPant
Target
SMN2
Pathway
PI3K/AKT
ObesitySCLCProstate Ca
Development Pipeline
Preclinical
Apr 2017
→ Oct 2029
PreclinicalCurrent
NCT07087256
1,623 pts·Obesity
2023-05→TBD·Active
NCT07019332
1,179 pts·Prostate Ca
2017-04→2029-10·Active
2,802 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-10-213.6y awayInterim· Prostate Ca
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Active
Preclinical
Active
Catalysts
Interim
2029-10-21 · 3.6y away
Prostate Ca
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07087256 | Preclinical | Obesity | Active | 1623 | PASI75 |
| NCT07019332 | Preclinical | Prostate Ca | Active | 1179 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 |